Detecting Cancer While It Is Still Small Impacts Survival
the ONA take:
Detecting breast cancers when they are small still impacts survival despite the various effective therapies, a study published in The BMJ has shown.
Because breast cancer survival rates have significantly improved over the last few decades, mostly due to earlier diagnosis and more effective treatment options, traditional prognostic factors such as tumor size and number of positive lymph nodes are thought to no longer affect survival.
Therefore, researchers in the Netherlands sought to compare survival by tumor size and nodal status in patients with breast cancer during 1995 to 2005 with 2006 to 2012.
Researchers analyzed the overall survival data of 173,797 female patients with breast cancer. They found that tumors diagnosed during the 2006 to 2012 period were smaller, less likely to be lymph node positive, and more often low grade.
Patients with diagnoses during that time were also more likely to have undergone breast-conserving therapy, and the use of hormonal therapy, chemotherapy, and drug therapy were increased.
Results showed that relative survival rates and overall survival rates were higher for the 2006 to 2012 cohort for all tumor and nodal stages, particularly in women ages 75 years and older. The study demonstrated that both tumor stage and nodal status had a significant impact on overall survival in patients from both groups.
“Through public health screening and innovations in treatment, we are making steady progress against breast cancer,” the authors write. “A challenge ahead is to help other societies build models of screening and treatment that foster the access and success of the Dutch experience.”
Detecting breast cancers when they are small still impacts survival despite the various effective therapies.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|